| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AIF1 |
| Uniprot No | P55008 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-147aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSQTRDLQGGKAFGLLKAQQEERLDEINKQ FLDDPKYSSDEDLPSKLEGFKEKYMEFDLNGNGDIDIMSLKRMLEKLGVP KTHLELKKLIGEVSSGSGETFSYPDFLRMMLGKRSAILKMILMYEEKARE KEKPTGPPAKKAISELP |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AIF1(Allograft Inflammatory Factor 1)重组蛋白的3篇代表性文献摘要(注：以下内容为模拟示例，具体文献需根据实际检索结果调整)：
1. **文献名称**：*"Recombinant AIF1 enhances macrophage activation through TLR4 signaling in inflammatory responses"*
**作者**：Li, X. et al.
**摘要**：研究通过大肠杆菌表达系统制备重组人AIF1蛋白，发现其能显著促进巨噬细胞的炎症因子(如TNF-α、IL-6)分泌，并激活TLR4和MAPK信号通路，提示AIF1在炎症性疾病中的调控作用。
2. **文献名称**：*"Expression and purification of functional AIF1 protein in E. coli for immunological studies"*
**作者**：Zhang, Y. et al.
**摘要**：报道了一种高效表达和纯化重组AIF1蛋白的方法，通过优化密码子和诱导条件提高蛋白可溶性，并验证其与免疫细胞表面受体的结合能力，为后续功能研究提供技术基础。
3. **文献名称**：*"AIF1-mediated microglial activation contributes to neuroinflammation in a mouse model of multiple sclerosis"*
**作者**：Wang, H. et al.
**摘要**：利用重组AIF1蛋白处理小胶质细胞，发现其通过激活STAT3通路促进促炎因子释放，并在实验性自身免疫性脑脊髓炎(EAE)模型中加重神经炎症，表明AIF1是神经免疫疾病的潜在治疗靶点。
4. **文献名称**：*"Recombinant AIF1 promotes vascular smooth muscle cell migration via NF-κB pathway in atherosclerosis"*
**作者**：Chen, L. et al.
**摘要**：研究发现重组AIF1蛋白可增强血管平滑肌细胞的迁移能力，并激活NF-κB信号通路，提示其在动脉粥样硬化等血管病变中的促纤维化作用。
如需具体文献，建议通过PubMed或Web of Science检索关键词“AIF1 recombinant protein”或“AIF1 expression and function”获取最新研究。
AIF1 (Allograft Inflammatory Factor 1), also known as Ionized Calcium-Binding Adapter Molecule 1 (Iba1), is a 17-kDa calcium-binding protein primarily expressed in macrophages, microglia, and other immune cells. It was first identified in the 1990s as a key mediator in chronic inflammatory responses within transplanted allografts. The protein contains two EF-hand calcium-binding domains, enabling it to regulate cytoskeletal reorganization, phagocytosis, and cell migration during immune activation. Its expression is strongly upregulated under inflammatory conditions, making it a biomarker for activated macrophages and microglia in diseases like atherosclerosis, autoimmune disorders, and neurodegenerative conditions.
Recombinant AIF1 protein is produced using biotechnological systems (e.g., E. coli or mammalian cell cultures) to study its molecular mechanisms and therapeutic potential. Researchers employ it to investigate its dual roles in inflammation: while AIF1 promotes pro-inflammatory cytokine release and immune cell infiltration, it also participates in tissue repair processes. Studies link AIF1 overexpression to pathologies such as rheumatoid arthritis, diabetic retinopathy, and tumor microenvironment modulation. Conversely, AIF1 knockout models show attenuated inflammatory responses, highlighting its central role in immune regulation.
In neuroscience, recombinant AIF1 helps explore microglial activation in Alzheimer’s and Parkinson’s diseases. Its interaction with signaling pathways like NF-κB and MAPK is of particular interest for drug development. However, conflicting evidence about its pro- versus anti-inflammatory effects underscores the need for further research. As a recombinant tool, AIF1 enables mechanistic studies, antibody production, and high-throughput screening for therapies targeting chronic inflammation and immune dysregulation.
×
